IMAXIO

Strategic area of application
Human Medicine

Application market
Infectiology - Parasitology

Activities
Therapeutics, Pharma or Biotech

Technologies
Vaccine

Presentation of company's activity
PHARMACEUTICAL PRODUCTS: IMAXIO has acquired the company Axcell Biotechnologies in 2009, including its vaccine against the human leptospirosis, which is currently marketed in France. Leptospirosis is an infectious disease caused by bacteria, leptospires, which are very mobile in humid natural environments. Although it is often benign, this disease can be acute and result in renal insufficiency, and even death in 5% to 10% of untreated cases.

Key features of company
PHARMACEUTICAL PRODUCTS: Unique vaccine available in Europe against human leptospirosis.

Skills and know-how
- Marketing and distribution of pharmaceutical products

Product pipeline 1

Therapeutic area: Vaccine

Therapeutic indication: Infectious diseases

MA: 1

Partnership opportunity
IMAXIO has an international business presence with partnerships for the distribution of the leptospirosis vaccine, and plans to extend its activities into new markets, most notably in Europe via a number of distribution partnerships. For the French market, IMAXIO is open to the establishment of agreements for distribution and product purchasing licenses, whether in the fields of workplace health and safety or travel-related illness.

Out-licencing opportunity
Imaxio is looking for acquiring pharmaceutical products or distribution licenses of pharmaceutical products to market in France, in order to consolidate its healthcare portfolio. Please, feel free to contact us for more information.

In-licencing opportunity
Imaxio is looking for acquiring pharmaceutical products or distribution licenses of pharmacuetical products to market in France or in Europe, in order to consolidate its healthcare portfolio. Please, feel free to contact us for more information.